Gilead Sciences has received several price target increases from analysts, with Oppenheimer and JPMorgan raising their targets to $105, while BMO Capital Markets set theirs at $102. Despite a "Moderate Buy" rating, top analysts favor five other stocks over Gilead. Insider trading activity shows significant sales, with insiders offloading over 63,000 shares in the past ninety days.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
